Stock DNA
Real Estate Development
PLN 20 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-999,999.00
-171.66%
20.14
Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.32%
0%
-7.32%
6 Months
-2.56%
0%
-2.56%
1 Year
63.44%
0%
63.44%
2 Years
12.43%
0%
12.43%
3 Years
-26.21%
0%
-26.21%
4 Years
-65.45%
0%
-65.45%
5 Years
-73.24%
0%
-73.24%
MEDCAMP SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-0.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
15.39%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.45%
ROE (avg)
0.04%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
22.36
EV to EBIT
-16.75
EV to EBITDA
-16.75
EV to Capital Employed
-21.16
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-171.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Jun 2023
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.10
-0.10
Interest
0.00
0.00
Exceptional Items
0.40
-0.30
233.33%
Consolidate Net Profit
0.10
-0.10
200.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024
Consolidated Net Profit
YoY Growth in quarter ended Mar 2025 is 200.00% vs 88.89% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.20
-3.20
93.75%
Interest
0.00
0.00
Exceptional Items
1.30
-5.10
125.49%
Consolidate Net Profit
1.20
-8.70
113.79%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 113.79% vs -58.18% in Dec 2023
About MEDCAMP SA 
MEDCAMP SA
Real Estate Development
Medcamp SA, formerly T2 Investment SA, is a Poland-based company engaged in the real estate operations. The Company is involved in the acquisition, management, redevelopment and upgrade, as well as rental and sale of commercial properties, including office areas and warehouses. In addition, the Company is involved in long-term investments in construction and real estate entities. It conducts rental and redevelopment projects, such as Poznan, Jasielska; Poznan, Komorniki; Poznan, Jasielska, Inkubator; Szamotuly, Dworcowa; among others. The Company aims to build a research and development center in Poznan, specializing in such areas as personalized medicine, genetics, genomics and bioinformatics, supported by artificial intelligence, The Company operates through subsidiaries, including T2 Inkubator Sp z o o, T2 Szamotuly Sp z o o, Polskie Centrum Badan i Rozwoju Sp z o o, among others. The majority shareholder of the Company is Moonrock Enterprise SA.
Company Coordinates 
Company Details
Ul. Jeleniogorska 16 C/3 , POZNAN None : 60-179
Registrar Details






